Table 1.
STAT3/CDK2/CDK4/CDK6 immunohistochemistry profile of cancer cohorts from human protein atlas database (HPA).
| Cancer Types | Sample in HPA | Patient Age | Patient Gender | Tumor-Histology | ||
|---|---|---|---|---|---|---|
| Total Sample | High Antibody Detected | Mean Age | Male n (%) |
Female n (%) |
Patient Tumor-Histology (%) | |
| CDK2 (Antibody: CAB013115) | ||||||
| Breast | 11 | 6 (54.54%) | 54.16 | - | 6 (100%) | DCN (33.33%) and LCN (66.66%) |
| Head and Neck | 4 | 4 (100 %) | 56.75 | 2 (50.00%) | 2 (50.00%) | HN-SCC (50.00%) and HN-ADC (50.00%) |
| Glioma | 11 | 7 (63.63%) | 58.14 | 5 (83.33%) | 3 (16.66%) | HGG (57.14%), LGG (42.85%) |
| Colorectal | 10 | 10 (100%) | 69.90 | 6 (60.00%) | 4 (40.00%) | C-ADC (70.00%), R-ADC (20.00%) |
| Prostate | 10 | 5 (50.00%) | 59.44 | 5 (100%) | - | HG_PA (60.00%) and LG_PA (40.00%) |
| Lung | 10 | 6 (60.00%) | 58.83 | 3 (50.00%) | 3 (50.00%) | L-SSC (66.66%) and L-AND (33.33%) |
| Liver | 11 | 4 (36.36%) | 63.50 | - | 4 (100.00%) | CCN (25.00%) and HCN (75.00%) |
| Pancreatic | 12 | 6 (50.00%) | 64.16 | 3 (50.00%) | 3 (50.00%) | PAC (100.00%) |
| CDK4 (Antibody: CAB013116) | ||||||
| Breast | 11 | 9 (81.81%) | 64.00 | - | 9 (100%) | DCN (55.55%) and LCN (44.44%) |
| Head and Neck | 4 | 4 (100%) | 71.5 | 3 (75.0%) | 1 (25.00%) | HN-SCC (75.00%) and HN-ADC (35.00%) |
| Glioma | 11 | 9 (81.81%) | 48.11 | 5 55.55%) | 4 (44.44%) | HGG (55.55%) and LGG (44.44%) |
| Colorectal | 12 | 12 (100%) | 79.50 | 6 (50.00%) | 6 (50.00%) | C-ADC (66.66%) and R-ADC (33.33%) |
| Prostate | 11 | 10 (90.90%) | 58.80 | 10 (100%) | - | HG_PA (70.00%) and LG_PA (30.00%) |
| Lung | 12 | 12 (100%) | 67.58 | 7 (58.33%) | 5 (41.66%) | L-SSC (58.33%) and L-AND (41.66%) |
| Liver | 12 | 8 (66.66%) | 63.25 | 5 62.55%) | 3 (37.5%) | CCN (25.00%) and 6 HCN (75.00%) |
| Pancreatic | 11 | 7 (63.63%) | 63.71 | 4 (57.15%) | 3 (42.85%) | PAC (100.00%) |
| CDK6 (Antibody: HPA002637) | ||||||
| Breast | 12 | 3 (25.00%) | 54.00 | - | 3 (100%) | DCN (75.00%) and LCN (25.00%) |
| Head and Neck | 4 | 4 (100.00%) | 58.25 | 1 (25%) | 3 (75%) | HN-SCC (50.00%) and HN-ADC (50.00%) |
| Glioma | 12 | 11 (91.66%) | 44.58 | 3 (100%) | - | HGG (63.63%) and LGG (36.36%) |
| Colorectal | 10 | 9 (90.00%) | 61.60 | 6 (66.6%) | 3 (33.33%) | C-ADC (66.66%) and R-ADC (6.33%) |
| Prostate | 10 | 2 (20.00%) | 66.00 | 2 (100%) | - | HG_PA (50.00%) and LG_PA (50.00%) |
| Lung | 11 | 4 (36.36%) | 61.00 | 2 (50%) | 2 (50%) | L-SSC (75.00%) and L-AND (25.00%) |
| Liver | 12 | 9 (75.00%) | 62.77 | 5 (55.55%) | 4 (44.5%) | CCN (66.66%) and HCN (33.33%) |
| Pancreatic | 11 | 7 (63.63%) | 62.00 | 3 (42.85%) | 4 (57.1%) | PAC (100.00%) |
| STAT3 (Antibody: HPA001671) | ||||||
| Breast | 11 | 11 (100%) | 63.18 | - | 11 (100%) | DCN (72.72%) and LCN (27.27%) |
| Head and Neck | 4 | 4 (100%) | 70.50 | 3 (75.00%) | 1 (25.00%) | HN-SCC (75.00%) and HN-ADC (25.00%) |
| Glioma | 12 | 5 (41.66%) | 45.60 | 2 (40.00%) | 3 (60.00%) | HGG (80.00%) and LGG (20.00%) |
| Colorectal | 12 | 12 (100%) | 64.83 | 4 (33.33%) | 8 (66.66%) | C-ADC (75.00%) and R-ADC (25.00%) |
| Prostate | 10 | 9 (90.00%) | 67.44 | 10 (100%) | - | HG_PA (88.88%) and LG_PA (11.11%) |
| Lung | 12 | 6 (50.00%) | 69.50 | 4 (66.66%) | 2 (33.33%) | L-SSC (50.00%) and L-AND (50.00%) |
| Liver | 11 | 4 (36.36%) | 57.75 | 2 (50.00%) | 2 (50.00%) | CCN (5000%) and 6 HCN (50.00%) |
| Pancreatic | 9 | 6 (66.66%) | 63.71 | 3 (50.00%) | 3 (50.00%) | PAC (100.00%) |
Key: DCN: duct carcinoma; LCN: lobular carcinoma; HN-SCC: head and neck squamous cell carcinoma; HN-ADC: head and neck adenocarcinoma; HGG: high grade glioma; LGG: low grade glioma; C-ADC: colon adenocarcinoma; R-ADC: rectum adenocarcinoma; HG_PA: high grade prostate adenocarcinoma; LG_PA: low grade prostate adenocarcinoma; L-SSC: lung squamous cell carcinoma; L-AND: lung adeno carcinoma; CCN: cholangiocarcinoma; HCN: hepatocellular carcinoma; PAC: pancreatic adenocarcinoma.